Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 177

Sort by

Sort Order Select

Journal Articles

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Loretta J. Nastoupil, MD MSc, Jason R. Westin, MD, Fredrick B. Hagemeister, MD, Hun Ju Lee, Luis Fayad, MD, Felipe Samaniego, MD, Sairah Ahmed, MD, Linda Claret, Raphael E Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Maria Alma Rodriguez, MD, Michael L. Wang, MD, Michael R Green, PhD, Eric Davis, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD

Blood (2019) 134 (Supplement_1): 125.

https://doi.org/10.1182/blood-2019-129422

Published: 2019

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

Myelodysplastic Syndromes: Trends in Mortality, Costs of Hospitalizations, Length of Stay and Rate of Complications

Shivani Handa, MBBS, Giulia Petrone, MD MBBS, Kamesh Gupta, MBBS, Ahmad Khan, MD, Jasdeep Singh Sidhu, MBBS, Sridevi Rajeeve, MD

Blood (2019) 134 (Supplement_1): 1725.

https://doi.org/10.1182/blood-2019-129365

Published: 2019

Journal Articles

Real-World Outcomes for 205 Danish Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Kathrine Aarup, Lisbeth Enggaard, MD, Robert Schou Pedersen, MD PhD, Rasmus Heje Thomsen, Olav Jonas Bergmann, Mikael Frederiksen, Ilse Christiansen, Tine Nielsen, Henrik Frederiksen, MD Prof, Carsten Utoft Niemann, MD PhD Ass. Prof, Michael Asger Andersen, MD

Blood (2019) 134 (Supplement_1): 1767.

https://doi.org/10.1182/blood-2019-123011

Published: 2019

Journal Articles

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Basem M. William, MRCP,MD, Ying Huang, MS, MA, Amy Johnson, MD, Jonathan E Brammer, MD, John C. Reneau, MD PhD, Joseph Maakaron, MD, Ruth Larbi, Cara Grantier, CNP, MPH, MS, Corinne Hoffman, MS, CNP, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MDMS, Beth A. Christian, MD, Lapo Alinari, MD PhD, Kami J. Maddocks, MD, Catherine Chung, MD

Blood (2019) 134 (Supplement_1): 2853.

https://doi.org/10.1182/blood-2019-123801

Published: 2019

Journal Articles

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, Jagan R. Muppidi, MD PhD, Craig A. Portell, MD, Rafic Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Lydia L. Chou, CRNP, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Louis Staudt, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 2867.

https://doi.org/10.1182/blood-2019-125990

Published: 2019

Journal Articles

Safety Profile of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor: A Meta-Analysis of Randomized Controlled Trials

Apoorva Krishna Chandar, MDMPH, Omar Ali Alaber, MD, Muhammad Zain Farooq, MD MBBS, Basma Ali Dahash, MD, Ankit Mangla, MBBS, MD

Blood (2019) 134 (Supplement_1): 4890.

https://doi.org/10.1182/blood-2019-127782

Published: 2019

Journal Articles

Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies

Julie Kanter, MD, Darla K Liles, MD, Kim Smith-Whitley, MD, Clark Brown, MD PhD, Abdullah Kutlar, MD, Brian Elliott, Amit Shah, Jeremie Lincy, Susan Poggio, Kenneth I. Ataga, MBBS

Blood (2019) 134 (Supplement_1): 991.

https://doi.org/10.1182/blood-2019-123965

Published: 2019

Journal Articles

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Beth A. Christian, MD, Ying Huang, MS, MA, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Jonathan E Brammer, MD, Narendranath Epperla, MDMS, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD, Farrukh T. Awan, MD, Kami J. Maddocks, MD, Kristie A. Blum, MD

Blood (2019) 134 (Supplement_1): 4082.

https://doi.org/10.1182/blood-2019-126242

Published: 2019

Journal Articles

Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)

Moshe Mittelman, MD, Uwe Platzbecker, MD, Boris Afanasyev, MD PhD, Sebastian Grosicki, MD PhD, Maria Socorro O Portella, MD MBA, Zewen Zhu, Dominik Selleslag, MD

Blood (2019) 134 (Supplement_1): 3740.

https://doi.org/10.1182/blood-2019-130309

Published: 2019

Journal Articles

Infections Associated with CAR T Therapy for Treatment of Hematological Malignancies

Tariq Iqtidar Sadiq Syed, MD, Syed Maaz Abdullah, MBBS, Tayyab Rehan, MBBS, Muhaddis Ejaz Ahmad, MD, Syeda Sabeeka Batool, MBBS, MD, Muhammad Abdullah Yousaf, MBBS, MD, Maaz Ahmed Yusufi, MD, Saif Ur Rehman, MBBS, MD, Sravanthi Kotapati, MBBS, Maimoona Khan, MBBS, Asma Waheed, MBBS, Zainab Ijaz, Awais Ijaz, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 4442.

https://doi.org/10.1182/blood-2019-127452

Published: 2019

Journal Articles

Caplacizumab As Step-up Therapy in Refractory TTP Utilizing Adamts-13 Activity and Evidence of End-Organ Damage

Neel Belani, MD, Adriel Barrios-Anderson, Sc.B, A.B., William Rafelson, MDMBA, Matthew I. Quesenberry, MD, Rabin Niroula, MBBS

Blood (2019) 134 (Supplement_1): 4909.

https://doi.org/10.1182/blood-2019-123206

Published: 2019

Journal Articles

Infectious Complications Associated with CAR T-Cell Therapy

Lekha Mikkilineni, MD, Shilpa Shahani, MD, Bonnie Yates, NP, Seth M. Steinberg, PhD, Tara Palmore, MD, Veronique Nussenblatt, MD, Daniel W. Lee, MD, Rosandra N. Kaplan, MD, Crystal L. Mackall, MD, Terry J. Fry, MD, Juan Gea-Banacloche, MD, Theresa Jerussi, James N. Kochenderfer, MD, Nirali N. Shah, MD

Blood (2019) 134 (Supplement_1): 4449.

https://doi.org/10.1182/blood-2019-131170

Published: 2019

Journal Articles

Interim Analysis of Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) in Taiwan

Hsin-An Hou, Chien-Chin Lin, MD, Ming-Chung Kuo, MD, Shyuann-Yuh Lin, MD, Jyh-Pyng Gau, MD, Ming-Chung Wang, MD, Ming-Chih Chang, MD, Tsung-Chih Chen, MD, Su-Peng Yeh, MD, Yeu-Chin Chen, MD, Cih-En Huang, MD, Chieh-Wen Chen, MD, Yee-Ming Lee, PhD, Fan-Chen Ku, MD, Lee-Yung Shih, MD

Blood (2019) 134 (Supplement_1): 5374.

https://doi.org/10.1182/blood-2019-129645

Published: 2019

Journal Articles

Localized Pulmonary Amyloidosis: A Single Institution Experience

Ajay Tambe, MBBS, Poornima Ramadas, MBBS, Mijung Lee, MD, Kanish Mirchia, MD

Blood (2019) 134 (Supplement_1): 5464.

https://doi.org/10.1182/blood-2019-125124

Published: 2019

Journal Articles

Complete Hematologic and Cytogenetic Remission of Acute Myeloid Leukemia in an Elderly Patient Treated with Decitabine and Venetoclax: A Case Report

Hanrry Jerry Paredes, MD MT(ASCP), M. Francisco Gonzalez, MD

Blood (2019) 134 (Supplement_1): 5189.

https://doi.org/10.1182/blood-2019-132019

Published: 2019

Journal Articles

Analysis of Predictive Factors for Early Response to Ruxolitinib in 266 Patients with Myelofibrosis from the Polish Adult Leukemia Group (PALG) Registry

Blood (2019) 134 (Supplement_1): 4180.

https://doi.org/10.1182/blood-2019-125864

Published: 2019

Journal Articles

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 4254.

https://doi.org/10.1182/blood-2019-123946

Published: 2019

Journal Articles

Urine Proteomic Analysis Reveals Disease-Specific Patterns in Pediatric Patients with Classical Hodgkin's Disease(HD). an Addon Study to the Euronet-PHL-C2 Trial

Blood (2019) 134 (Supplement_1): 2804.

https://doi.org/10.1182/blood-2019-125611

Published: 2019

Journal Articles

Relapsed Follicular Lymphoma and Haploidentical Transplantation Using Double Source of Hematopoietic Stem Cells and Post-Transplant Cyclophosphamide: Case Report

Ana Rojas Fonseca, Nelson Hamerschlak, MD PhD, José Salvador Rodrigues de Oliveira, MD PhD

Blood (2019) 134 (Supplement_1): 5718.

https://doi.org/10.1182/blood-2019-125208

Published: 2019

NARROW

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Myelodysplastic Syndromes: Trends in Mortality, Costs of Hospitalizations, Length of Stay and Rate of Complications

Real-World Outcomes for 205 Danish Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Safety Profile of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor: A Meta-Analysis of Randomized Controlled Trials

Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)

Infections Associated with CAR T Therapy for Treatment of Hematological Malignancies

Caplacizumab As Step-up Therapy in Refractory TTP Utilizing Adamts-13 Activity and Evidence of End-Organ Damage

Infectious Complications Associated with CAR T-Cell Therapy

Interim Analysis of Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) in Taiwan

Localized Pulmonary Amyloidosis: A Single Institution Experience

Complete Hematologic and Cytogenetic Remission of Acute Myeloid Leukemia in an Elderly Patient Treated with Decitabine and Venetoclax: A Case Report

Analysis of Predictive Factors for Early Response to Ruxolitinib in 266 Patients with Myelofibrosis from the Polish Adult Leukemia Group (PALG) Registry

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Urine Proteomic Analysis Reveals Disease-Specific Patterns in Pediatric Patients with Classical Hodgkin's Disease(HD). an Addon Study to the Euronet-PHL-C2 Trial

Relapsed Follicular Lymphoma and Haploidentical Transplantation Using Double Source of Hematopoietic Stem Cells and Post-Transplant Cyclophosphamide: Case Report

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only